4basebio PLC (AIM: 4BB)
Health Care · Biotechnology · GB
£4.70
-14.55% today · -38.2% 1Y
4basebio PLC (AIM: 4BB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $115.78M.
Over the last twelve months the share price has lost 38.2%, trading between 4.20 and 9.30.
Tweenvest scores 4basebio PLC across four factors: quality 24/100, value 41/100, growth 100/100. Its strongest factor is growth.
4BB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $115.78M
- Revenue (TTM)
- $2.28M
- P/E
- —
- EPS
- -1.09
- Dividend yield
- —
- Beta (5Y)
- 0.87
- 52-week high
- £9.30
- 52-week low
- £4.20
- Avg volume (3M)
- —
- Shares outstanding
- 15.54M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.